Skip to main content

Table 1 Baseline characteristics of 114 patients initially presenting with TTC

From: Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy

Variables No catecholamines (n = 93) catecholamines(n = 21) p value*
Demographics
 Age, mean ± SD 67.65 ± 11.00 65.00 ± 12.30 0.33
 Male, n (%) 13 (13.97) 6 (28.57) 0.11
Symptoms, n (%)
 Dyspnoe 34 (36.55) 9 (42.85) 0.62
 Chest pain 52 (55.91) 6 (28.57) 0.03
Clinic parameter
 Systolic BP, mmHg 134.96 ± 28.41 116.25 ± 42.32 0.01
 Diastolic BP, mmHg 78.41 ± 13.67 66.55 ± 31.22 0.03
 Heart rate, bpm 98.17 ± 27.64 110.95 ± 22.79 0.05
ECG Data, n (%)
 ST-segment elevation 27 (29.03) 7 (33.33) 0.79
 Inversed T-Waves 83 (89.24) 19 (90.47) 0.74
 PQ-interval 160.67 ± 27.97 160.00 ± 34.38 0.92
 QTc (ms), mean ± SD 484.49 ± 50.83 455.30 ± 52.82 0.02
Stress factor, n (%)
 Emotional sress 28 (30.10) 2 (9.52) 0.05
 Physical stress 50 (53.76) 14 (66.66) 0.33
Laboratory values, mean ± SD
 Troponin I (U/L) 3.20 ± 4.41 6.57 ± 8.46 0.01
 Creatine phosphatkinase (U/L) 721.11 ± 2900.64 323.74 ± 469.71 0.55
 CKMB 37.44 ± 65.08 31.00 ± 23.56 0.77
 C-Reactive protein (mg/l) 42.63 ± 64.25 80.30 ± 126.15 0.06
 Hemoglobin 12.10 ± 1.99 12.29 ± 2.08 0.70
 Creatinine (mg/dl) 1.14 ± 0.76 1.19 ± 0.50 0.79
 GFR < 60 ml/min 25 (26.88) 7 (33.33) 0.59
Echocardiography data, n (%)
 LV EF % 39.67 ± 9.12 32.76 ± 9.09 < 0.01
 Follow-up LV EF % 55.23 ± 7.54 48.63 ± 14.90 < 0.01
 Apical ballooning 64 (68.81) 18 (85.71) 0.15
 Mitral regurgation 50 (53.76) 10 (47.61) 0.63
 Tricspid regurgation 42 (45.16) 7 (33.33) 0.46
 RV-Involvement 17 (18.27) 9 (42.85) 0.02
Medical history, n (%)
 Smoking 30 (32.25) 6 (28.57) 0.80
 Diabetes mellitus 22 (23.65) 4 (19.04) 0.64
 Obesity (BMI > 25 kg/m2) 27 (29.03) 4 (19.04) 0.75
 Hypertension 54 (58.06) 12 (57.14) 1.00
 COPD 19 (20.43) 7 (33.33) 0.25
 Atrial fibrillation 15 (16.12) 6 (28.57) 0.21
 Coronary artery disease 16 (17.20) 6 (28.57) 0.23
 History of malignancy 13 (13.97) 3 (14.28) 0.97
Drugs on admission, n (%)
 Beta-blocker 32 (34.40) 3 (14.28) 0.06
 ACE inhibitor 30 (32.25) 5 (23.80) 0.45
 ASS 24 (25.80) 5 (23.80) 0.87
 Anticoagulation 7 (7.52) 0 (0) 0.19
  1. *p values for the comparison between group 1 and group 2; SD Standard deviation, ECG Electrocardiogram, EF Ejection fraction, BMI body-mass-index, COPD Chronic obstructive pulmonary disease, ACE Angiotensin-convetring-enzyme
  2. EFhochversusnichthoch*Katecholaminpflichtigkeit: 0.000
  3. The bolded indication highlight significant values